An inhibitory metabolite leads to dose- and time-dependent pharmacokinetics of (R)-N-{1-[3-(4-ethoxy-phenyl)-4-oxo-3,4-dihydro-pyrido[2,3-d]pyrimidin-2-yl]-ethyl}-N-pyridin-3-yl-methyl-2-(4-trifluoromethoxy-phenyl)-acetamide (AMG 487) in human subjects after multiple dosing.

Tonn, George R; Wong, Simon G; Wong, Sylvia C; Johnson, Michael G; Ma, Ji; Cho, Robert; Floren, Leslie C; Kersey, Kathryn; Berry, Karen; Marcus, Andrew P; Wang, Xuemei; Van Lengerich, Bettina; Medina, Julio C; Pearson, Paul G; Wong, Bradley K

Tonn, George R; Wong, Simon G; Wong, Sylvia C; Johnson, Michael G; Ma, Ji; Cho, Robert; Floren, Leslie C; Kersey, Kathryn; Berry, Karen; Marcus, Andrew P; Wang, Xuemei; Van Lengerich, Bettina; Medina, Julio C; Pearson, Paul G; Wong, Bradley K.

Afiliação

Tonn GR; Department of Pharmacokinetics, Amgen Inc., South San Francisco, California, USA. george.tonn@elan.com

Drug Metab Dispos ; 37(3): 502-13, 2009 Mar.

Article em En | MEDLINE | ID: mdl-19088267

Assuntos

Acetamidas/farmacocinética; Pirimidinonas/farmacocinética; Receptores CXCR3/antagonistas & inibidores; Acetamidas/administração & dosagem; Adulto; Área Sob a Curva; Cromatografia Líquida; Estudos de Coortes; Inibidores das Enzimas do Citocromo P-450; Esquema de Medicação; Humanos; Masculino; Pirimidinonas/administração & dosagem; Espectrometria de Massas em Tandem

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirimidinonas / Receptores CXCR3 / Acetamidas Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Humans / Male Idioma: En Ano de publicação: 2009 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google